Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
Crossref DOI link: https://doi.org/10.1186/s12885-017-3679-5
Published Online: 2017-10-17
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ungari, Andrea Queiróz
Pereira, Leonardo Régis Leira
Nunes, Altacílio Aparecido
Peria, Fernanda Maris